Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.
NCT01808456 is a phase 4 interventional trial sponsored by Inova Health Care Services. As of 21 Nov 2026, it is completed. It studies Influenza trivalent inactive vaccine and Influenza trivalent inactive vaccine high dose in Influenza, Human and Transplantation Infection. The registry lists an enrollment of 62 participants at 1 site in 1 country. The registry lists a start date of 31 Oct 2013 and a primary completion date of 31 Dec 2016.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT01808456 |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional trial |
| Lead sponsor | Inova Health Care Services |
| Enrollment | 62 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Influenza, Human and Transplantation Infection |
| Drugs | Influenza trivalent inactive vaccine and Influenza trivalent inactive vaccine high dose |
| Start | 31 Oct 2013 |
| Primary completion | 31 Dec 2016 |
| Study completion | 31 Dec 2016 |
| Last update posted | 22 Jul 2022 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Ravinder Wali, MD
Inova Fairfax Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Inova Fairfax Hospital
Falls Church
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT01808456
Each answer restates registry values shown on this page.
What is NCT01808456?
NCT01808456 is a phase 4 interventional trial sponsored by Inova Health Care Services. It studies Influenza trivalent inactive vaccine and Influenza trivalent inactive vaccine high dose in Influenza, Human and Transplantation Infection.
Who leads NCT01808456?
The registry names Ravinder Wali, MD (principal investigator, Inova Fairfax Hospital) as the overall official.
Where does NCT01808456 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT01808456 study?
The registered drug and biological interventions are Influenza trivalent inactive vaccine and Influenza trivalent inactive vaccine high dose.
When did NCT01808456 end?
The registry lists a primary completion date of 31 Dec 2016 and a study completion date of 31 Dec 2016. The sponsor last updated the record on 22 Jul 2022.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.